Clinical Trials
67 trialsMK-4280A-007
Merck Sharp & Dohme LLC
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
Bayer
CodeBreak300
Amgen
GISTAR-1
Ningbo Newbay Technology Development Co., Ltd
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Nanjing Sanhome Pharmaceutical, Co., Ltd.
MK-7902-017
Merck Sharp & Dohme LLC
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Shanghai JMT-Bio Inc.
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
CheckMate 9N9
Bristol-Myers Squibb
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC
STELLAR-303
Exelixis
ARC-9
Arcus Biosciences, Inc.
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
RELATIVITY-123
Bristol-Myers Squibb
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
Great Novel Therapeutics Biotech & Medicals Corporation
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
Bayer
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Shanghai Runshi Pharmaceutical Technology Co., Ltd
ROCKET
EpicentRx, Inc.
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Sumitomo Pharma America, Inc.
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Hoffmann-La Roche
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Bayer
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Bayer
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
CStone Pharmaceuticals
A Study of CS1003 in Subjects With Advanced Solid Tumors
CStone Pharmaceuticals
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
Maxinovel Pty., Ltd.
A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
Bayer
GRID
Bayer
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Novartis
RESORCE
Bayer
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
US Oncology Research
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
Hoffmann-La Roche
BAY73-4506 Probe Substrate Study
Bayer
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Bayer
REGARD
Bayer
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Bayer
Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
Bayer
Study of Ruxolitinib in Colorectal Cancer Patients
Incyte Corporation